High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: A phase II study by the Japan adult leukemia study group

Journal of Clinical Oncology

Volumn 24, Issue 3, 2006, Pages 460-466

  Yanada, Masamitsu ^a   Takeuchi, Jin ^b   Sugiura, Isamu ^b   Akiyama, Hideki ^b   Usui, Noriko ^b   Yagasaki, Fumiharu ^b   Kobayashi, Tohru ^b   Ueda, Yasunori ^b   Takeuchi, Makoto ^b   Miyawaki, Shuichi ^b   Maruta, Atsuo ^b   Emi, Nobuhiko ^b   Miyazaki, Yasushi ^b   Ohtake, Shigeki ^b   Jinnai, Itsuro ^b   Matsuo, Keitaro ^b   Naoe, Tomoki ^b   Ohno, Ryuzo ^b  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; IMATINIB; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; VINCRISTINE; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT OUTCOME; ACUTE LYMPHOCYTIC LEUKEMIA; DRUG ANTAGONISM; FEASIBILITY STUDY; JAPAN; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; REMISSION; SURVIVAL;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEASIBILITY STUDIES; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; JAPAN; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33644845774     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.2177     Document Type: Article

References (29)

1. Hermans A, Heisterkamp N, von Linden M, et al: Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell 51:33-40, 1987
2. Chan LC, Karhi KK, Rayter SI, et al: A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature 325: 635-637, 1987
3. Clark SS, McLaughlin J, Timmons M, et al: Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science 239:775-777, 1988
4. Lugo TG, Pendergast AM, Muller AJ, et al: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247:1079-1082, 1990
5. Faderl S, Kantarjian HM, Talpaz M, et al: Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 91:3995-4019, 1998
6. Larson RA, Dodge RK, Burns CP, et al: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and leukemia group B study 8811. Blood 85:2025-2037, 1995
7. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: Correlations with hematologic findings outcome: A collaborative study of the Group Francais de Cytogenetique Hematologique. Blood 87:3135-3142, 1996
8. Seeker-Walker LM, Prentice HG, Durrant J, et al: Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA - MRC Adult Leukaemia Working Party. Br J Haematol 96:601-610, 1997
9. Ueda T, Miyawaki S, Asou N, et al: Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: The ALL90 study of the Japan Adult Leukemia Study Group. Int J Hematol 68:279-289, 1998
10. Wetzler M, Dodge RK, Mrozek K, et al: Prospective karyotype analysis in adult acute lymphoblastic leukemia: The Cancer and Leukemia Group B experience. Blood 93:3983-3993, 1999
11. Thomas X, Danaila C, Le QH, et al: Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: A single institution experience of 378 consecutive patients over a 21-year period. Leukemia 15:1811-1822, 2001
12. Gleissner B, Gokbuget N. Bartram CR, et al: Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: A prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 99:1536-1543, 2002
13. Takeuchi J, Kyo T, Naito K, et al: Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: The JALSG-ALL93 study. Leukemia 16:1259-1266, 2002
14. Annino L, Vegna ML, Camera A, et al: Treatment of adult acute lymphoblastic leukemia (ALL): Long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 99:863-871, 2002
15. Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001
16. Ottmann OG, Druker BJ, Sawyers CL, et al: A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100:1965-1971, 2002
17. Thomas DA, Faderl S, Cortes J, et al: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103:4396-4407, 2004
18. Towatari M, Yanada M, Usui N, et al: Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 104: 3507-3512, 2004
19. Ottmann OG, Wassmann B, Pfeifer H, et al: Imatinib given concurrently with induction chemotherapy is superior to imatinib subsequent to induction and consolidation in newly diagnosed Philadelphia positive acute lymphoblastic leukemia (PH+ALL). Blood 104:197a, 2004 (abstr 685)
20. Lee S, Kim YJ, Min CK, et al: The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 105:3449-3457, 2005
21. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
22. Schrappe M, Arico M, Harbott J, et al: Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: Good initial steroid response allows early prediction of a favorable treatment outcome. Blood 92:2730-2741, 1998
23. Roy A, Bradburn M, Moorman AV, et al: Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: Results of the Medical Research Council ALL 97 trial. Br J Haematol 129: 35-44, 2005
24. Chao NJ, Blume KG, Forman SJ, et al: Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 85:3353-3354, 1995
25. Sierra J, Radich J, Hansen JA, et al: Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 90:1410-1414, 1997
26. Cornelissen JJ, Carston M, Kollman C, et al: Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: Strong graft-versus-leukemia effect and risk factors determining outcome. Blood 97:1572-1577, 2001
27. Esperou H, Boiron JM, Cayuela JM, et al: A potential graft-versus- leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from the French Bone Marrow Transplantation Society. Bone Marrow Transplant 31:909-918, 2003
28. Faderl S, Kantarjian HM, Thomas DA, et al: Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma 36:263-273, 2000
29. Thomas DA, Faderl S, Cortes J, et al: Update of the hyper-CVAD and imatinib mesylate regimen in Philadelphia (Ph) positive acute lymphocytic leukemia (ALL). Blood 104:748a, 2004 (abstr 748)